Amgen Inc. (NASDAQ:AMGN) Stock Position Increased by First United Bank & Trust

First United Bank & Trust boosted its position in Amgen Inc. (NASDAQ:AMGN) by 2.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,258 shares of the medical research company’s stock after purchasing an additional 126 shares during the quarter. First United Bank & Trust’s holdings in Amgen were worth $2,016,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Regatta Capital Group LLC increased its stake in Amgen by 2.7% during the 3rd quarter. Regatta Capital Group LLC now owns 6,083 shares of the medical research company’s stock valued at $1,960,000 after buying an additional 159 shares during the period. Magnus Financial Group LLC increased its stake in Amgen by 15.2% during the 3rd quarter. Magnus Financial Group LLC now owns 896 shares of the medical research company’s stock valued at $289,000 after buying an additional 118 shares during the period. Lockerman Financial Group Inc. increased its stake in Amgen by 4.4% during the 3rd quarter. Lockerman Financial Group Inc. now owns 1,261 shares of the medical research company’s stock valued at $406,000 after buying an additional 53 shares during the period. Members Trust Co increased its stake in Amgen by 6.8% during the 3rd quarter. Members Trust Co now owns 1,655 shares of the medical research company’s stock valued at $533,000 after buying an additional 105 shares during the period. Finally, Swedbank AB increased its stake in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after buying an additional 5,751 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AMGN shares. TD Cowen lifted their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Bank of America lifted their price objective on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. Cantor Fitzgerald began coverage on shares of Amgen in a research report on Friday, September 27th. They issued an “overweight” rating and a $405.00 target price on the stock. Finally, Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $326.95.

Amgen Price Performance

NASDAQ AMGN opened at $325.09 on Wednesday. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The stock has a market capitalization of $174.39 billion, a PE ratio of 46.44, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a 50 day moving average price of $325.97 and a two-hundred day moving average price of $311.49. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. Amgen’s revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the firm earned $5.00 earnings per share. As a group, equities analysts predict that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio is 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.